Chand Hari Jung, Rijal Komal Raj, Neupane Biswas, Sharma Vijay Kumar, Jha Bharat
Tribhuvan University, Kirtipur, Kathmandu, Nepal.
J Infect Dev Ctries. 2014 Nov 13;8(11):1483-7. doi: 10.3855/jidc.4228.
Enteric fever is endemic in Nepal and poses a significant public health burden. The first-line drugs ampicillin, chloramphenicol, and cotrimoxazole have not been part of empirical therapy for two decades due to the development of multidrug-resistant Salmonella strains. The objective of this study was to determine the antibiogram pattern of Salmonella serovars isolated from the blood of clinically suspected enteric fever patients.
A cross sectional study was carried out in a tertiary care hospital in Lalitpur, Nepal, between July 2011 and February 2012. Standard microbiological procedures were followed during collection and processing of blood samples, isolation and identification of Salmonella serotypes. The antimicrobial sensitivity of ampicillin, chloramphenicol, cotrimoxazole, nalidixic acid, and ciprofloxacin was determined using a modified Kirby-Bauer disk diffusion method as per the guidelines of the Clinical and Laboratory Standards Institute.
Out of 86 Salmonella isolates, 56 (65.1%) were Salmonella Typhi and 30 (34.9%) were Salmonella Paratyphi A. Salmonella Typhi were 100% sensitive to chloramphenicol, cotrimoxazole, and ciprofloxacin and 98.2% sensitive to ampicillin. Similarly, Salmonella Paratyphi A isolates were 100% sensitive to ampicillin and cotrimoxazole and 96.7% sensitive to chloramphenicol and ciprofloxacin. More than 90.0% of isolates were nalidixic acid resistant and none of the Salmonella isolates were multi-drug resistant.
This study revealed the increasing frequency of nalidixic acid-resistant Salmonella isolates, indicating the possibility of fluoroquinolone resistance in near future. Furthermore, re-emergence of susceptibility to conventional first-line drugs ampicillin, chloramphenicol, and cotrimoxazole supports the possibility of using these drugs in empirical therapy.
伤寒在尼泊尔呈地方流行性,给公共卫生带来重大负担。由于多重耐药沙门氏菌菌株的出现,一线药物氨苄西林、氯霉素和复方新诺明在二十年来一直未被纳入经验性治疗药物。本研究的目的是确定从临床疑似伤寒患者血液中分离出的沙门氏菌血清型的抗菌谱模式。
2011年7月至2012年2月期间,在尼泊尔拉利特布尔的一家三级护理医院开展了一项横断面研究。在采集和处理血样、分离和鉴定沙门氏菌血清型的过程中遵循了标准微生物学程序。根据临床和实验室标准协会的指南,采用改良的 Kirby-Bauer 纸片扩散法测定氨苄西林、氯霉素、复方新诺明、萘啶酸和环丙沙星的抗菌敏感性。
在86株沙门氏菌分离株中,56株(65.1%)为伤寒沙门氏菌,30株(34.9%)为甲型副伤寒沙门氏菌。伤寒沙门氏菌对氯霉素、复方新诺明和环丙沙星的敏感性为100%,对氨苄西林的敏感性为98.2%。同样,甲型副伤寒沙门氏菌分离株对氨苄西林和复方新诺明的敏感性为100%,对氯霉素和环丙沙星的敏感性为96.7%。超过90.0%的分离株对萘啶酸耐药,且没有沙门氏菌分离株为多重耐药。
本研究揭示了萘啶酸耐药沙门氏菌分离株的频率增加,表明在不久的将来可能出现氟喹诺酮耐药。此外,对传统一线药物氨苄西林、氯霉素和复方新诺明敏感性的重新出现支持了在经验性治疗中使用这些药物的可能性。